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INTRODUCTION
Thymic epithelial tumors are the most common type of malignancy arising in the anterior mediastinum and include thymoma and thymic carcinoma; the latter is a relatively rare, high grade malignancy that directly invades adjacent structures and also undergoes distant metastasis. The most effective therapeutic modality for treating thymic carcinoma is surgical complete resection, 1, 2 which 7
To this end, the present study investigated PD-L1 expression in thymic carcinoma and its correlation with clinicopathological features including PD-1 + TIL numbers and patient prognosis.
Copy number alterations of the PD-L1 gene were also examined, and their relationship to PD-L1 expression was assessed.
MATERIALS AND METHODS

Patients
Formalin-fixed, paraffin-embedded (FFPE) tissue samples acquired from 25 newly The immunoreaction was visualized by treatment with diaminobenzidine chromogen (Dako) for 5 minutes. Each slide was evaluated by two investigators (YS and MH) who were blinded to any clinical information, and discrepancies were debated until a consensus was reached.
Appraisal of PD-L1 expression
Quantification of PD-L1 expression
PD-L1 expression was assessed under 400-fold magnification using an optical microscope in an entire field for each TMA spot and was quantified by the H-score approach, in which the proportion and intensity of tumor cells positive for PD-L1 is determined. 23, 27 Specifically, the PD-L1
staining intensity of individual tumor cells was graded from 0 to 3 (0, negative; 1, weak; 2, moderate;
3, strong). The proportion of tumor cells exhibiting each intensity level with respect to the entire tumor cell population was calculated. The H-score was defined as the sum of the values obtained by multiplying the staining intensity and proportion, and ranged from 0 to 300 (Fig. 1) .
PD-L1 expression (H-score) cutoff value determination
The optimal cutoff value for PD-L1 expression was defined based on the receiver operating characteristic curve and Youden's index. 28, 29 Here, Masaoka-Koga stage and surgical curability were taken into account as variables that significantly affect prognosis. real-time PCR system. Results were analyzed using CopyCaller Software (Applied Biosystems).
Statistical analysis
The relationship between PD-L1 positivity and clinicopathological features was evaluated using Fisher's exact test for categorical variables. The Mann-Whitney U test was used to compare the median value of continuous variables according to PD-L1 positivity as well as PD-L1 expression based on PD-L1 copy number status. Pearson's product-moment correlation coefficient was used to determine the correlation between PD-L1 expression and the number of TIA-1 + or granzyme B + TILs.
In the analysis of recurrence and survival, the starting point was defined as the day of surgical resection or biopsy. The end of the disease-free survival (DFS) period was defined as the day of recurrence, and that of the OS period was defined as the day of death or the date of last follow-up, respectively. Survival curves to estimate DFS and OS were determined by the Kaplan-Meier method, with comparison of each curve using a log-rank test. Cox proportional hazards regression models were used to assess the prognostic values of each factor. P-values declared in this study were all based on two-sided tests, and those less than 0.05 were interpreted as statistically significant. JMP version 11 software (SAS Institute Inc., Cary, NC) was used to perform all statistical analyses.
RESULTS
Clinicopathological findings
The baseline clinicopathological features of patients are summarized in Supplementary 
Multivariate analysis of prognostic factors affecting overall survival
Although a larger multivariate model was used to identify prognostic factors, the results had limited value because of the small number of samples (Supplementary Table S2 ). For reference, all potential prognostic factors identified in the univariate analysis retained their significance in the multivariate analysis, represented as Masaoka-Koga stage (HR, 7.000; P = 0.005), surgical curability (HR, 7.000; P = 0.005), PD-L1 expression (HR, 6.854; P = 0.028), and the number of PD-1 + TILs (HR, 1.546; P = 0.026). In addition, these factors were prognostically significant in patients with squamous cell carcinomas.
Correlation between PD-L1 expression and cytotoxic T lymphocyte abundance
To further characterize TILs and assess the association between high PD-L1 expression and improved survival, we evaluated TIA-1 expression in TILs which is a representative marker of cytotoxic cells. Based on morphological findings, the acquired knowledge of antitumor immunity principled by T cells, 14 
DISCUSSION
This study demonstrated for the first time that high PD-L1 expression is associated with favorable OS in thymic carcinoma. This result was supported by the finding that high PD-L1 expression was correlated with an increase in CTL infiltration. Furthermore, we also found that an increase in the number of PD-1 + TILs predicted poor patient survival. These results suggest that the PD-1/PD-L1 pathway is a potential immunotherapeutic target in thymic carcinoma.
The PD-L1 copy number analysis demonstrated that PD-L1 expression was significantly higher in cases with PD-L1 copy number gain than in normal cases, implying that PD-L1 gene alteration is an important mechanism of PD-L1 overexpression. Previous studies that focused on B cell lymphomas have also reported that PD-L1 transcripts are more highly expressed in tissue samples and cell lines with increased PD-L1 copy number than in normal cases, although it was not possible to make a direct comparison. 31, 32 To clarify the exact biological mechanisms underlying PD-L1 overexpression in thymic carcinoma, additional studies and data on transcriptional levels are required. Furthermore, PD-L1 was found to be amplified in 27% of thymic carcinomas. Although
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few studies have evaluated genetic copy number aberrations in thymic carcinoma, relationships between poor OS and BCL2 copy number gain or CDKN2A/B copy number loss have been observed, the frequency of which was 42% and 14%, respectively. 33 Further studies on genetic alterations in the tumor are necessary to improve therapeutic strategies and survival for thymic carcinoma patients.
Thus far, few studies have examined PD-L1 expression in thymic epithelial tumors.
22-24
Confined to thymic carcinoma as a subset of thymic epithelial tumors, only one of these reports mentioned the prognostic role of PD-L1, finding that there was no difference in OS according to PD-L1 positivity. 23 However, our results indicated a significant association between high PD-L1 expression and better prognosis. This discrepancy may be attributable to differences in patient selection; the previous study evaluated thymoma and thymic carcinoma collectively, whereas thymomas and heterogeneous cases of combined thymoma and thymic carcinoma were excluded from the present study. We consider that thymoma and thymic carcinoma should be analyzed individually because they are widely known to vary in terms of prognosis and molecular biological profiles. 26 In fact, when the 25 thymic carcinoma samples evaluated here were analyzed along with 82 thymoma samples in our previous study, 24 OS was comparable between cases with high and low PD-L1 expression in both individual histology types; thymic carcinoma, however, demonstrated slightly higher PD-L1 positivity than thymoma, consistent with the previous report. Nevertheless, our study analyzed thymic carcinoma independently and found that high PD-L1 expression was associated with favorable survival. Thus, thymic carcinoma and thymoma should be investigated
Research. independently to clarify the role of PD-L1 expression in each tumor type.
The prognostic value of PD-L1 expression has been investigated for various malignancies, including malignant melanoma, non-small cell lung cancer, and renal cell carcinoma. [34] [35] [36] Most studies have emphasized an association between high PD-L1 expression and poor survival based on the ability of PD-L1 to negatively regulate antitumor T cell responses. In contrast, high PD-L1 expression has been linked to better prognosis in some malignancies. 17, 35, 37 In these reports, a significant association between high PD-L1 expression and increased TILs was identified. It is still controversial which anti-PD-L1 antibody is the best to determine PD-L1 expression by IHC in tumor tissue samples. This is a critical issue because immunohistochemical PD-L1 positivity has been reported to predict therapeutic efficacy in anti-PD-1/PD-L1 antibody immunotherapy in several clinical trials, as mentioned previously. In the present study, the PD-L1 clone EPR1161 [2] , which recognizes the C-terminus extracellular domains of PD-L1, was employed.
By contrast, previous reports studying PD-L1 in thymic epithelial tumors used clone 5H1, which targets extracellular domains of PD-L1, or E1L3N, which targets intracellular domains, 
retrospective analysis, which may have resulted in selection bias because of the various therapeutic protocols that were used. Therefore, prospective studies are also needed to validate our findings.
In conclusion, the present study demonstrated that high PD-L1 expression by tumor cells was associated with favorable prognosis, whereas an increased number of PD-1 + TILs was correlated with poor prognosis in thymic carcinoma. These indicators can be used to stratify patients for more effective clinical management. Importantly, our findings provide a basis for the use of immunotherapy targeting the PD-1/PD-L1 pathway as a potential novel treatment in thymic carcinoma.
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